Non-coding RNA Research (Dec 2023)

Expression profile of LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 in patients with preeclampsia

  • Shymaa E. Ayoub,
  • Olfat G. Shaker,
  • Rehab Abdelhamid Aboshama,
  • Mohamed K. Etman,
  • Abeer A. Khalefa,
  • Mohamed M. khamiss Abd elguaad,
  • Othman M. Zaki,
  • Doaa Y. Ali,
  • Nada F. Hemeda,
  • Amal Amin,
  • Marwa A. Ali

Journal volume & issue
Vol. 8, no. 4
pp. 481 – 486

Abstract

Read online

Preeclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Several studies demonstrated the role of lncRNAs and miRNAs in the pathogenesis of preeclampsia; the aim was to detect the expression profiles of serum LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 in patients with preeclampsia. The study included 160 subjects divided into 80 subjects considered as a control group, 80 patients with preeclampsia. We found that there was a significant difference between the preeclampsia and control groups with up-regulation of miR-186 median (IQR) = 4, 29 (1.35–7.73) (P < 0.0001), miR-181a median (IQR) = 2.45 (0.83–6.52) (P = 0.028), and downregulation of lncRNA ANRIL median (IQR) = 0.35(0.28–0.528) (P < 0.0001), MTMR median (IQR) = 0.32(0.155–1.11), (P < 0.0001). ROC curve of lncRNA ANRIL, miR-186, miR-181a, and MTMR-3 in preeclampsia patients showing the roles of these markers in the diagnosis of preeclampsia. In conclusion, serum LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 could be promising biomarkers in the diagnosis of preeclampsia.

Keywords